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Background: It had been reported that up to 37% of the adult male population smokes cigarettes in Qatar. The
Global Youth Tobacco Survey also stated that 13.4% of male school students aged 13 to 15 years in Qatar smoke
cigarettes. Smoking cessation is key to reducing smoking-related diseases and deaths. Healthcare providers are in
an ideal position to encourage smoking cessation. Pharmacists are the most accessible healthcare providers and
are uniquely situated to initiate behavior change among patients. Many studies have shown that pharmacists can
be successful in helping patients quit smoking. Studies demonstrating the effectiveness of pharmacist-delivered
smoking cessation programs are lacking in Qatar. This proposal aims to test the effect of a structured smoking
cessation program delivered by trained ambulatory pharmacists in Qatar.
Methods/Design: A prospective, randomized, controlled trial is conducted at eight ambulatory pharmacies in
Qatar. Participants are randomly assigned to receive an at least four-session face-to-face structured patient-specific
smoking cessation program conducted by the pharmacist or 5 to 10 min of unstructured brief smoking cessation
advice (emulating current practice) given by the pharmacist. Both groups are offered nicotine replacement therapy
if feasible. The primary outcome of smoking cessation will be confirmed by an exhaled carbon monoxide test at
12 months. Secondary outcomes constitute quality-of-life adjustment as well as cost analysis of program resources
consumed, including per case and patient outcome.
Discussion: If proven to be effective, this smoking cessation program will be considered as a model that Qatar and
the region can apply to decrease the smoking burden.
Trial registration: Clinical Trials NCT02123329.
Keywords: Qatar, Tobacco control, Smoking cessation, PharmacistBackground
The leading preventable cause of ill health today is
cigarette smoking [1]. It is a major risk factor for several
causes of death including heart disease, chronic lung
diseases and lung cancer [2]. It kills one in ten adults
globally and causes more than 5 million deaths annually.
If present trends continue, the number of smoking-
related deaths is expected to reach more than 8 million* Correspondence: maguyh@qu.edu.qa
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unless otherwise stated.deaths per year by 2030 [3]. The adverse health conse-
quences of tobacco use not only compromise smokers’
quality of life, but also entail significant direct and indirect
economic costs on society. The 2008 World Health
Organization (WHO) report states that the global health-
care costs attributable to tobacco use reach hundreds of
billions of US dollars each year [4]. Smoking cessation is
key to reducing the number of smoking-related diseases
and deaths. At any age, quitting smoking improves quality
of life (QoL) and confers considerable health benefits
including reduced risk of coronary heart disease, strokeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gests that if adult tobacco consumption were to decrease
by 50% by the year 2020, approximately 180 million
tobacco-related deaths could be avoided between now and
2050 [7]. Health professionals are in an ideal position to
encourage smoking cessation. A short intervention by
them can considerably increase the smoking cessation rate
[8]. Of all health professionals, pharmacists are the most
easily accessed by the public and are uniquely situated to
initiate behavior change among smokers [9]. They can
provide education and advice without prior appointment
and with no direct or additional cost to individuals [10].
They regularly interact with patients obtaining medications
for smoking-related diseases. In addition, the increased
availability of pharmacologic smoking cessation aids includ-
ing some formulations of nicotine replacement therapy
over the counter in pharmacies in many countries gives the
pharmacists a distinct opportunity to serve as front-line
health providers who can play a major smoking cessation
role [11]. Moreover, available data support the provision of
smoking cessation services in ambulatory and community
pharmacies. Many studies have shown that pharmacists can
be effective providers of tobacco cessation interventions
and can be successful in helping patients quit smoking
[12-20] and that these pharmacy interventions can be
cost-effective or cost-beneficial [21-24]. Additionally, in
many countries there is extensive support at the profes-
sional level for the involvement of pharmacists in smoking
cessation. The Canadian Pharmacists Association devel-
oped a Joint Statement on Smoking Cessation. This state-
ment promotes the involvement of health professionals
including pharmacists in tobacco prevention and cessation
[8]. The International Pharmaceutical Federation (FIP)
issued a statement of policy on the role of pharmacists
in promoting a tobacco-free future [25]. The European
Forum adopted a pharmacists’ charter on action against
smoking, which states that pharmacists should consider
smoking cessation as an essential element of their profes-
sional responsibilities [26]. The US Public Health Service
published evidence-based clinical guidelines recommend-
ing that all health care providers, including pharmacists,
should offer smoking-cessation interventions [27]. The
American Society of Health-System Pharmacists’ (ASHP)
Therapeutic Position Statement on the Cessation of To-
bacco Use strongly encourages pharmacists as well as
other healthcare providers to integrate identification of to-
bacco users and delivery of tobacco-cessation interven-
tions into their routine patient care. As per the ASHP
statement, these interventions should address five key ele-
ments of comprehensive tobacco cessation counseling
(the 5 As): (1) asking patients about tobacco use, (2) advis-
ing users to quit, (3) assessing their readiness to quit, (4)
assisting them with quitting using behavior modification
and smoking cessation medications, and (5) arrangingfollow-up care. If comprehensive tobacco-cessation coun-
seling cannot be provided because of time constraints or
practice site logistics, pharmacists can use a truncated 5 A
model whereby they ask about tobacco use, advise tobacco
users to quit, and then refer patients to smoking cessation
providers or programs [28].
In Qatar, tobacco use is a major public health problem
that, in addition to the associated morbidity and mortal-
ity, constitutes a huge burden on healthcare services. To
control tobacco use, Qatar has adopted the international
approaches recommended by the World Health Organ-
ization (WHO) and regional plan of Arab countries in the
Gulf. These approaches are based on three strategies:
(1) imposing legislative tobacco control measures, for
example, banning smoking in enclosed public places
and prohibiting selling cigarettes, tobacco or its deriva-
tives to anyone less than 18 years old, (2) providing
smoking cessation services for free in two hospital-
based smoking cessation clinics and (3) implementing
antismoking public awareness activities [29]. Despite
these approaches, in Qatar up to 37% of adult males
currently smoke tobacco [30] and 13.4% of male school
students aged 13 to 15 years smoke cigarettes according
to the 2007 Global Youth Tobacco Survey [31]. Further-
more, smoking-related diseases are the most prevalent in
Qatar. Ischemic heart disease, as an example, was ranked
as one of the leading causes of burden of disease in Qatar
in 2010 [32], and Qatar has a higher age standardized lung
cancer incidence rate than many countries in the Gulf
(8.95 per 100,000) [33]. In addition, according to a recent
survey done by Weill Cornell Medical College in Qatar, at
least 1 billion cigarettes are smoked in Qatar each year,
averaging 12,000 per individual, and 65 million US dollars
(USD) are spent on cigarettes annually; 150 million USD
are used to cover the healthcare costs of patients affected
by smoking-related diseases [34]. The potential for
pharmacist-assisted tobacco cessation is therefore huge
and could have a considerable impact on smoking rates,
prevention of tobacco-related diseases and enhancement
of public health in Qatar. Around 700 registered pharma-
cists practice in public and private ambulatory care clinics
and in community pharmacies in Qatar. If each of these
pharmacists successfully assists just one tobacco user in
quitting each month, this would result in more than
8500 quitters annually. However, according to a study
conducted by Qatar University’s College of Pharmacy
and funded by the Qatar Foundation under its Under-
graduate Research Experience Program (UREP), Qatar’s
ambulatory and community pharmacists are not fully
engaged in smoking cessation activities. Eighty percent
of Qatar’s ambulatory and community pharmacists rarely,
never or sometimes ask their patients about their smoking
status, and 53% rarely, never or sometimes offer smoking
cessation counseling to nicotine therapy purchasers.
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macists discuss the adverse health effects of smoking,
41% assist them in quitting and 16% arrange follow-up
sessions with them to assess their progress in quitting
smoking. However, more than 85% of pharmacists are
interested in providing smoking cessation counseling
and believe that it is an important activity [35]. The
pharmacists’ perceptions regarding the importance of
smoking cessation can be transformed into action if a
smoking cessation model is provided that these phar-
macists can use in routine practice. Unfortunately, an
intensive, patient-specific program of smoking cessation
designed exclusively for implementation in community
and ambulatory pharmacies is not available in Qatar. In
addition, evidence regarding the effect of such a program
is lacking in Qatar.
Also important, in addition to the numerous knowledge
gaps identified above in relation to Qatar, there are also no
data on how cost beneficial the running of smoking cessa-
tion programs like the currently proposed one is, added to
a lacking data on the associated resource implications in
the pharmacy setting from the Qatari perspective.
Study objectives
This proposal describes a study that is currently being im-
plemented in eight public and private ambulatory clinic
pharmacies in Qatar. Our hypothesis is that a patient-
specific structured smoking cessation program delivered
by smoking cessation-trained ambulatory pharmacists
would be significantly more effective in helping smokers
stop smoking and achieving long-term smoking abstin-
ence than brief unstructured pharmacist-delivered advice.
We also hypothesize that quitting smoking would lead
to significant improvement in health-related quality of life.
The study objectives are:
 Primary: To test the effect of a face-to-face structured
patient-specific smoking cessation program delivered
by trained ambulatory pharmacists on smoking
cessation rates in Qatar
 Secondary: To assess the change in health-related
quality of life in quitters vs. non-quitters
 Secondary: To explore the resource utilization of
implementing the smoking cessation program as
delivered by the ambulatory pharmacists in Qatar.
This is a cost analysis of the overall cost of running




The study is a prospective randomized controlled trial
comparing the effectiveness of a face-to-face structured
patient-specific smoking cessation program conductedby trained ambulatory pharmacists versus brief unstruc-
tured pharmacist-delivered advice on smoking cessation
rates.Study sites
The study is implemented in eight public and private
ambulatory pharmacies in the State of Qatar. These
pharmacies are located within large ambulatory clinics
that serve a large proportion of the Qatar population.
To prevent cross contamination with the study, none of
these clinics has established smoking cessation programs.
Each study pharmacy is staffed by at least three pharma-
cists. Two pharmacists from each pharmacy are invited to
participate in the study. The study is taking place in a
semiprivate area in the pharmacy. This area is secluded
enough to ensure adequate patient confidentiality.Study pharmacists’ training
Prior to starting the study, each study site pharmacist
was sent a copy of the study methodology along with a
written literature review on smoking cessation and asked
to study the material.
Two to three weeks after receipt of the material, the
study pharmacist attended a 2-day (8 h/day) smoking cessa-
tion training workshop that was organized by the Hamad
Medical Corporation (HMC) smoking cessation clinic team
and Qatar University (QU) College of Pharmacy.
The training team consisted of Dr. Ahmed al Mulla
(Public Health and Disease Control Consultant and HMC
smoking cessation clinic head), Dr. Maguy El Hajj (Study
Principal Investigator/Assistant Professor and CPP Chair
at QU College of Pharmacy), Dr. Nadir Kheir (Associate
Professor and CPPD coordinator at QU College of
Pharmacy) and Dr. Mohamad Haniki Nik Mohamed
[Deputy Dean (Academic Affairs) in Kulliyyahof Pharmacy
at the International Islamic University Malaysia (IIUM)].
Dr. Haniki is considered an international authority in the
area of substance abuse, including cigarette smoking.
The HMC smoking cessation clinic is one of the smok-
ing cessation facilities in Qatar. The clinic is run by highly
qualified smoking cessation consultants and has a smok-
ing cessation success rate of 40%. In addition to offering
smoking cessation treatment, this clinic contributes to
community education on the dangers of smoking among
the citizens and residents of Qatar and provides smoking-
related lectures and seminars for all age groups in the
state [36].
The general objective of this workshop is to provide
the study pharmacists with enough smoking cessation
knowledge and the necessary skills and tools to assess
and treat smokers. A smoking cessation training manual
that was developed by the study training team is exten-
sively used in the workshop. This manual is also used as
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smoking cessation program.
The workshop covered the following: smoking epidemi-
ology and risks, benefits of quitting, a transtheoretical
model for behavior change as applied to smoking cessation,
the necessary elements for documentation in the patient
smoking cessation profile, behavioral modification tech-
niques, classification of smokers according to their stage of
change (5 stages: precontemplation, contemplation, prepar-
ation, action and maintenance), nicotine replacement ther-
apy (NRT: nicotine patch, lozenge and gum), patient
counseling techniques, development of a personalized
action plan, use of the exhaled carbon monoxide test,
detailed instructions on the program methodology and
other needed elements.
In addition, the pharmacists’ training workshop included
training the pharmacists on how to follow the study proto-
col exactly. The study team walked the pharmacists
through the study protocol including how to randomly
allocate participants to the intervention and control
groups, how to deliver the intervention and how to deal
with control patients.
During the training workshops, emphasis was also
placed on the importance of behavioral and lifestyle
modifications. Pharmacists were instructed to encourage
smokers who are anticipating quitting to identify the
situations that may increase their risk of smoking such
as having smokers within the household or at the work-
place as well as getting into stressful situations. After
identifying these situations, the pharmacists were pro-
vided with information they could give to smokers
about strategies to improve coping including lifestyle
changes to decrease stress and improve QoL, removing
visual cues for smoking and staying away from these
situations that normally make patients want to smoke
[37]. In addition, the pharmacists were trained to provide
the smokers with information about what to expect during
quit attempts and to address any individual concerns
that the smokers may have [38]. Furthermore, they
were advised to encourage the smokers to notify family
and friends of the plan to quit and to ask for their
support [37].
Participant counseling and interviewing techniques
were also part of the training workshops. To enhance
learning, the pharmacists applied these techniques using
patient role-plays in small groups. Topics that were
reviewed included counseling skills, verbal and nonver-
bal communication skills including use of empathy and
active listening, use of open-ended and priming ques-
tions, verification of patient understanding, overcoming
of communication barriers, communication with difficult
patients, communication with patients not interested in
discussing smoking cessation and use of strategies to
improve medication adherence.Documentation was an important element of the work-
shop. The pharmacists were trained to document the
patient’s smoking, medical and medication history, basic
demographic characteristics, staging, assessment, educa-
tion, counseling, follow-up and the personalized action
plan to quit smoking. In addition, they were instructed on
how to fill in the Fagerstrom test for nicotine dependence
(FTND). The FTND is a six-item questionnaire designed
to assist the healthcare professional in determining a pa-
tient’s degree of nicotine dependence [39]. This question-
naire has already been used in smoking-related research
studies in the Middle East area [40,41]. Furthermore,
they were instructed to measure the smoker’s health-
related QoL using the Smoking Cessation Quality of Life
(SCQOL) questionnaire. This instrument was developed
and validated for use in smoking cessation [42,43] and has
already been used in previous studies that tested the
effectiveness of a pharmacist-delivered smoking cessation
program [16]. This questionnaire tackles a total of 13 gen-
eral and smoking cessation-specific quality-of-life domains
including physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional,
mental health, social interactions, self-control, sleep, cog-
nitive functioning and anxiety [43].
Study/program marketing
The study pharmacists were trained to recognize many
opportunities for the promotion of the smoking cessa-
tion program as possible. For example, when dispensing
prescriptions, the study pharmacists were encouraged to
ask patients about smoking and to tell them about the
smoking cessation program. In addition, study site phar-
macists displayed posters and leaflets in their pharmacy
describing the smoking cessation program. Furthermore,
the general practitioners and dentists practicing in the
study ambulatory clinics were sent letters inviting them
to refer their patients who are interested in quitting to
the study pharmacies.
Screening and eligibility criteria
Interested smokers meet with the study pharmacists.
The study pharmacists use a scripted questionnaire to
screen smokers in order to assess their eligibility for the
study. Eligible participants are patients aged 18 years
and older who currently smoke one or more cigarettes
daily for 7 days, are motivated to quit, i.e., in the prepar-
ation stage of the stage-of-change model, able to com-
municate in Arabic or English, and are willing to and
capable of attending the scheduled sessions at the study
pharmacies. The motivation to quit is determined by the
pharmacist using the transtheoretical model of behavior
change [44]. Smokers in the precontemplation or con-
templation stages are advised to quit, are provided with
educational materials regarding tobacco cessation and
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come back to the pharmacy when they feel they are
ready to commit to quitting smoking.
Exclusion criteria are (1) use of other nicotine or to-
bacco products and (2) current use or use in the last 30
days of smoking cessation aids or medications, (3) plan-
ning to leave Qatar in the next 12 months, (4) presence of
any major medical condition that would prevent use of
the nicotine replacement therapy including hypersensitiv-
ity to the products, history of or recent myocardial infarc-
tion, life-threatening arrhythmias, severe or worsening
angina, uncontrolled hypertension and temporomandibu-
lar joint disease (in case of nicotine gum), (5) pregnancy
and (6) psychiatric illness or another debilitating condition
that would interfere with participation in the study.
Study enrollment
Following the completion of the screening procedure,
the study pharmacist gives the eligible participant pertin-
ent background information on the program, explaining
what his or her participation would involve (including
potential benefits, risks, inconveniences, discomforts),
and his or her right to confidentiality. In order to enroll
in the study, the interested participant is asked to sign
an approved consent form. Once the consent form is
signed, the pharmacist collects the participant’s contact
information and sets an appointment with him or her at
a date and time that is suitable for both of them.
Initial appointment and randomization
One to two days before his or her scheduled appoint-
ment, the study pharmacist contacts the enrolled partici-
pant to remind him or her about the appointment. At
this initial appointment, which takes around 30 min, the
study pharmacist first collects the participant’s sociode-
mographic characteristics, current medical problems and
medications, smoking history (i.e., number of cigarettes
per day, duration of smoking, previous quit attempts,
smoking habits of other family members and the partici-
pant’s reasons for wanting to quit smoking) and vital
signs (i.e., blood pressure and pulse). In addition, the
pharmacist assesses the smoker’s level of nicotine depend-
ence using the Fagerstrom Test for Nicotine Dependence
and measures his or her baseline exhaled carbon monoxide
(CO) level using the exhaled CO test. Furthermore, the
pharmacist administers the smoking cessation quality-of-
life (SCQOL) questionnaires. After baseline data collection,
the smoker is randomly assigned to either the intervention
group or the control group. Randomization is already an-
onymously preset by the study statistician for each study
pharmacist. According to the participant number and the
preset list, the participant will be randomized to the inter-
vention or control group. A new appointment is set with
the participants assigned to the intervention group.Participants assigned to the control group receive brief un-
structured smoking cessation advice as outlined below. Par-
ticipants in both groups do not pay for their participation.
Intervention group
Participants assigned to the treatment group participate in
a face-to-face four-session program at the pharmacy deliv-
ered by the study pharmacist at 2-4-week intervals over 8
weeks. The sessions are set at a date and time that are
convenient for both the pharmacist and participant.
First session
The first session is time-intensive, taking around 30 min.
In this session, the study pharmacist facilitates the partici-
pant’s preparation to quit. The participant selects a quit
date within the next 2-4 weeks. Based on the transtheore-
tical model of change, this would give him or her time to
get prepared to enter the action stage on the quit date.
The pharmacist discusses the benefits of smoking ces-
sation with the participant and provides him or her with
tailored behavioral and lifestyle strategies. These strat-
egies take into consideration the participant behaviors,
values and beliefs. For example, if the smoker states that
the hardest time would be at work when others are tak-
ing breaks to smoke, the pharmacist may suggest ways
to spend the time during breaks. As outlined under the
training section, the pharmacist also provides the partici-
pant with information about what to expect during the
quit attempt with suggestions to cope with the early days
of quitting. In addition, the pharmacist encourages the
participant to seek family support during the attempt.
To prevent nicotine withdrawal symptoms, the partici-
pant is also offered, without cost, nicotine replacement
therapy (NRT) as a patch or lozenge depending on his
or her previous experience, preference and adverse effect
profile. Other NRT dosage forms, e.g., an inhaler, nasal
spray and sublingual tablets, are not available in Qatar.
The gum is usually not tolerated by patients. The par-
ticipant is not offered the other smoking cessation aids,
including bupropion and varenicline, as they require a
prescription in order to be dispensed in Qatar. Before
dispensing the NRT, the study pharmacist ensures that
the participant does not have any contraindications to
nicotine therapy and is not taking any medication that
would interact with NRT. The NRT is started on the
participant’s intended quit date. Patient counseling about
NRT is provided to each participant regarding the dosage,
administration, scheduling, duration of therapy, adverse
effects, interactions and proper disposal.
Participants who take the nicotine patch start at 21 mg
if they smoke ten cigarettes or more per day. Otherwise,
they receive a 14-mg patch. Both patches are continued
for 6 weeks before being tapered. The 21-mg patch is de-
creased to 14 mg, continued for 2 weeks and decreased to
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mg patch are tapered to 7 mg for a final 2 weeks [45]. Par-
ticipants who take the nicotine lozenge use the 1-mg
pieces. It is continued for 6 weeks as one lozenge every 1-
2 h before being tapered. Then the participant takes one
lozenge every 2-4 h for weeks 7 to 9, then one lozenge
every 4-8 h for week 10-12 [46].
A personalized action plan is created by the pharmacist
to document the participant’s quit date, nicotine replace-
ment therapy dosage schedule and counseling, suggested
behavioral and lifestyle strategies, and date/time of the
next appointment. This plan is signed by both the partici-
pant and pharmacist.
Follow-up sessions
The first follow-up session is scheduled 1 week after of
the participant’s quit day and takes around 20 min. In
this session, the pharmacist determines the participant’s
smoking status, measures his or her blood pressure/
pulse/exhaled CO level, and assesses the NRT tolerabil-
ity. If the patient succeeds in quitting, the pharmacist
provides reinforcement and addresses problems associated
with quitting such as managing withdrawal symptoms,
coping with cravings, relieving stress, and managing
fear of weight gain and of change in relationships with
other smoking friends or relatives. If the participant
fails to quit smoking, the pharmacist carefully reviews
the participant’s experience during the attempt to quit
and works through the identified problems. If the
participant does not tolerate the NRT side effects (e.g.,
his or her blood pressure or heart rate increases), the
pharmacist asks the participant to stop the NRT and re-
fers him or her to the HMC smoking cessation clinic
for further smoking cessation support. This participant
is no longer enrolled in the study.
The second follow-up session is scheduled 2 weeks
after the first follow-up session. The third follow-up ses-
sion is set at 4 weeks after the second follow-up session.
These sessions take no more than 10 or 15 min each. In
these sessions the pharmacist assesses the participant’s
smoking status, blood pressure/heart rate/exhaled CO
level and NRT tolerability and provides NRT refills. In
addition, he or she focuses on maintenance of smoking
abstinence with cognitive-behavioral strategies to prevent
relapse. The pharmacist documents any action taken by
him/her at each follow-up session. After the third follow-
up session, all participants are instructed to call or visit
the pharmacy for questions or to receive additional sup-
port as needed. For more information on participant flow
during the study, see Figure 1.
Control group
Participants in the control group receive 5-10 min of
unstructured brief smoking cessation counseling by thepharmacist (emulating current practice). In addition,
they are provided with educational materials about
smoking cessation and are offered nicotine replacement
therapy (NRT). Before dispensing the NRT, the study
pharmacist ensures that the participant does not have
any contraindications to nicotine therapy and is not
taking any medication that would interact with NRT.
The choice of the NRT dosage form (patch or lozenge)
depends on the participant’s previous experience, prefer-
ence and adverse effect profile. The NRT dosage sched-
ule and duration of therapy are similar to those in the
intervention group. Control participants are not asked
to attend any follow-up sessions.
The education materials address the following topics:
the adverse effects of smoking, benefits of smoking cessa-
tion, the methods of quitting, setting the quit date, coping
with nicotine withdrawal symptoms, getting emotional
and social support, and monitoring the blood pressure
and pulse when using NRT and avoiding relapse.
The study team invests a good deal of time orienting
the study pharmacists on their role and training them
on how to deal with the control and intervention groups.
Part of that orientation is on how ‘not’ to provide any
intervention to the control subset of smokers.
Study piloting
Study pharmacists were provided with assistance in set-
ting up the study pharmacies and given some time to
familiarize themselves with the study protocol prior to
commencement of the study. Then each pharmacist was
asked to pilot the study in the presence of the study
team. Piloting occurred by screening/recruiting around
four patients in each site and by implementing the study
protocol. Feedback was provided as required to the study
pharmacists on the quality of patient counseling, patient
education and documentation. Very minor adjustments or
refinements were made to the study protocol and study
tools including the patient consent form, Fagerstrom test
for nicotine dependence (FTND) and smoking cessation
quality-of-life (SCQOL) questionnaire as needed.
Continuous quality improvement and evaluation plan
At all stages of the study implementation, the study
pharmacists are closely supervised by the study team.
Supervision is through several mechanisms including
meetings, communication and site visits.
Meetings
Regular meetings are invaluable for high-quality supervi-
sion. Meetings are used to guide the project toward its
objectives through team involvement. Bi- or triweekly
meetings involving all the team members including the
study pharmacists are held. In these meetings, study






Participants will be screened by the study pharmacists. 
Do they meet eligibility criteria?  
Eligible participants will be asked to participate 
Willing to sign informed consent? 
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Figure 1 Participant flow during the study.
El Hajj et al. Trials  (2015) 16:65 Page 7 of 122-3 weeks, and the study team offers them constructive
feedback, acknowledges their input and suggests new di-
rections to them. In addition, ad-hoc meetings are con-
ducted between the study pharmacists and the study team
where necessary to address any irregular issues that might
arise.
Communication
The study team members are in direct touch with each
other and with the study pharmacists through electronic
communication such as emails.
Site visits
To maintain quality control in the smoking cessation
study pharmacies, the study team visits each study phar-
macy at least once every 2 to 3 weeks to monitor data col-
lection, check protocol adherence, ensure the consistency
of program delivery, address any queries that the studypharmacists might have in implementing the study, review
patients’ folders for appropriate documentation, provide
any on-site support required and provide individual phar-
macists with feedback on their performance.
Supervision is crucial to:
 Orient study pharmacists to the study’s
objectives and methodology and to their role in
the study
 Monitor and follow-up the progress of the study
 Tackle any issues or concerns that might arise with
the study pharmacists while the study is executed
 Share study updates
 Motivate and support the study pharmacists
 Ensure adherence to the study protocol in the
different study sites
 Ensure standardization of study implementation in
the different study sites
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A comparative overview of the cost of resource utilization
(economic analysis) will be undertaken for the study arms
in this study.
Model inputs and cost determination
This pharmacoeconomic analysis will be based on extrapo-
lating data on resources from the randomized controlled
trial; these data will be collected prospectively. Prospective
data collection enhances the accuracy and robustness of
data and limits bias.
The economic analysis is performed from a social per-
spective. Direct medical costs will be evaluated to the best
available, including in relation to NRT, CO monitoring
tests and salaries. Direct nonmedical costs will also be
evaluated and will include participants’ travel costs to
pharmacies (e.g., taxi) and the paperwork and forms. The
indirect costs will be accounted for as well, in relation to
lost productivity (if any), whether for participants or any
unpaid caregivers that participants utilize. Important is
that any protocol-driven costs (e.g., researchers salaries)
will be excluded from the analysis.
The monetary value of resources will be collected from
internal sources at the Qatari clinics. It is worth noting
that costs involved in this study will be based on whole-
sale prices, as paid by clinics.
All calculated costs will be in Qatari Riyal, adjusted for
the financial year 2015-2016, utilizing the Qatari Health
Consumer Price Index as appropriate, and no discounts
will be applied given the short timeframe of the analysis.
The economic evaluation will be undertaken via deci-
sion analytic modeling, where a decision tree will be struc-
tured to follow the different options and consequences in
the management pathways. For each of the participants,
the proposed model may include five possible treatment
outcomes depending on whether participants quit smok-
ing, and if they do, after what duration. Smokers will be
initially assigned to one of two pathways depending on
whether they quit smoking at enrollment. Smokers who
do not quit at enrollment will be further followed until
assigned to one of two pathways, depending on whether
the smoker quits smoking after 3 months or not. If not,
smokers will be followed up until further assigned to one
of two pathways, based on whether they quit smoking
after 6 months or not. Those who do not quit by then will
be followed up until assigned to one of two pathways de-
pending on whether they quit at 12 months of follow-up
or not, which will be the end of follow-up in any case.
Smokers who quit at enrollment or after 3, 6 or 12 months
will each be followed up separately until the end of the
study. Based on this, in addition to data on resources con-
sumed and their monetary values, the model will generate
a weighted average cost for patient cessation and quality-
of-life adjustment. As per the general decision analysisprinciples, this will be calculated as the sum-product of
the costs of the management outcomes and the respective
probabilities.
The costs of managing the single episode of smoking
cessation will be compared among different management
options and against budgeted costs of clinics/govern-
ment institutions.
Sensitivity analysis
The goal of sensitivity analysis is to indicate the robust-
ness of the evaluation conclusion against any potential
variations in the model inputs. Deterministic and prob-
abilistic sensitivity tests will be produced by modifications
on the base case values of several key variables, in rele-
vance to costs and probabilities, to evaluate the robustness
of the study economic outcome. Base case values will be
substituted by the highest and lowest values within a rea-
sonable range of values. Where a substitution changes the
study economic conclusion, more values within the range
will replace the base case value. This will be repeated until
the exact variable value that changes the study outcome is
identified. Reporting this as part of the study results not
only indicates the robustness of results, but also boosts
the generalizability of them when being interpreted by
decision makers in other settings, with different model
inputs, e.g., different resource prices.
Uncertainty analysis, by means of Monte Carlo simula-
tion, will be performed via the @Risk-5.0® analysis tool
(Palisade Corp., NY, USA) to investigate the likelihood
(probability) of a therapy’s economic advantage. Monte
Carlo is a method whereby simulated input values,
chosen randomly across a range of probability distribu-
tions of a model input, are added into the model. The
model is run for each simulated input, resulting in a
range of outputs characterizing the output uncertainty.
Based on this, a distribution of “cost savings” will be
generated, indicating the probability of one management
option to have an economic advantage over another.
Ethical considerations and confidentiality
The study protocol and all associated measures, consent
forms and recruitment procedures obtained ethical ap-
proval by Qatar University (QU) and Hamad Medical
Corp. (HMC) institutional review boards (QU-IRB 76/11
and HMC 11113/11). All the participants’ folders are
stored in a password-protected database on the site lap-
top. Only the study pharmacist can access these folders. In
addition, all data are retained in a password-protected
database maintained along with all related study docu-
mentation in a locked cabinet at QU College of Pharmacy.
Outcome measures
The study research assistants will call the study partici-
pants in the intervention and control groups to complete
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research assistants will be blinded to the participant
group allocation.
They will measure the following outcome variables at
3, 6 and 12 months after the start of the study (i.e., the
time of the participant’s enrollment in the study):
 Self-reported 7-day point prevalence abstinence,
defined as having smoked no cigarettes for the
previous 7 days at 3, 6 and 12 months
 Self-reported 30-day point prevalence abstinence
defined as having smoked no cigarettes in the last
30 days at 3, 6 and 12 months
 Self-reported continuous abstinence defined as
having smoked no cigarettes since quit day at 3, 6
and 12 months
 Smoking abstinence as objectively verified by the
CO exhaled test at 12 months
 Mean change in health-related quality-of-life score
from baseline at 3, 6 and 12 months for quitters vs.
non-quitters
 Overall costs of interventions as studied, including
those of utilization for individual recourses consumed
 Average and incremental cost-effectiveness ratio of
the study smoking cessation intervention
To objectively determine long-term abstinence, at 12
months, participants who will self-report not smoking
for the previous 7 days will be invited to come to their
study clinic to measure their exhaled CO level. The clinic
nurse who is responsible for measuring the exhaled CO
level will be blinded to the study participant group. Partic-
ipants will be considered abstinent if they register less
than 6 ppm on the test. Interpretation of the CO test
results will be made carefully taking into consideration
time since last smoke, time of the day the test is done and
other factors.
Exhaled carbon monoxide is a well-known indicator of
cigarette smoking. But because of its short half-life (5-6 h),
it only indicates very recent smoking exposure or ab-
stinence. On the other hand, as a result of its relatively
long half-life, cotinine can detect nicotine exposure for
up to 1 week. However, the use of any NRT formulation
can trigger a false-positive urinary cotinine test. There-
fore, as it is not expensive and is noninvasive, and it
gives the results in a timely manner, the exhaled carbon
monoxide test is commonly used in most smoking ces-
sation clinical trials [47].
Data analysis
The CONSORT guidelines will be followed when analyz-
ing the study data. Demographics and other variables re-
lated to smoking and quality of life will be summarized
using frequency distributions (for categorical variables)and means with standard deviations (for numeric vari-
ables) and will be compared between the two study arms
using the chi-squared test (or alternatively the Fisher’s
exact test for small cell counts) for categorical variables
and the independent t-test (or alternatively the Wilcoxon
rank sum test for non-normally distributed variables) for
numerical variables.
The main outcome will be continuous abstinence at
12 months as self-reported and verified by the CO test.
The percentages of participants achieving the main out-
come will be computed and compared between the two
groups using the chi-squared test. Moreover, the differ-
ence in the proportions of continuous abstinence at 12
months between the two study arms (with 95% confi-
dence intervals) will be computed along with the num-
ber needed to treat. Multiple logistic regression will be
used to obtain the odds ratio of the main outcome be-
tween the two study arms adjusting for any imbalances
in demographics or other baseline smoking-related vari-
ables. Moreover, mixed effects logistic regression, with
pharmacy-level random effect, will be considered to ad-
just for the possible pharmacy effect if it existed. The
intent-to-treat principal will be used in the analysis
whereby participants who will be lost to follow-up will
be classified as smokers and included in the main ana-
lysis. This includes those who were removed from the
study because they could not tolerate NRT side effects.
A sensitivity analysis following that of Borelli, Hogan
et al. will be done where the outcome has three possible
categories: abstinence, no abstinence and dropout [48].
The suggested multinomial model will allow assessing
factors affecting abstinence as well as factors affecting
dropout. This will aid in understanding who might need
more support during the intervention. Similar analyses
for the primary outcome will be done at 3 and 6 months
(but do not include verification of abstinence using CO
tests).
To assess the participants’ health-related quality of
life, SCQOL (smoking cessation quality of life) ratings
for each question will be translated into scores. A total
health-related quality of life score and a domain-
specific score will be calculated at baseline, 3 months, 6
months and 12 months for each participant in the
intervention and control groups. The change in the
total and domain-specific quality-of-life score from
baseline will be calculated for each participant at 3, 6
and 12 months and analyzed using linear mixed
models, which will include the quitting (quitters and
non-quitters) factor and time factor (at 3, 6 and 12
months) and their interaction.
There is no interim analysis planned for this trial. Stat-
istical analyses will be conducted using the Statistical
Package of Social Sciences (IBM-SPSS®), version 21. In
all analyses, the level of significance will be set at 5%.
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For a priori sample size calculation, we assumed a 7-day
point prevalence abstinence at 12 months of 3% for the
control group and 15% for the intervention group based
on the results of one of the previous studies that
assessed the effect of a pharmacist-run smoking cessa-
tion program [12]. With a two-sided alpha of 5% and
90% power, a minimum sample size of 118 participants
was estimated for each group. This sample size was not
adjusted for the potential correlation between outcomes
of patients within each clinic since this is not a clustered
randomized clinical trial, but in this study patients
within each clinic are randomized to the two interven-
tion groups, and correlations, if they exist, will be very
small; their effect on the power of the study is negligible
[15]. The project has a total of 17 study pharmacists.
Each study site is expected to enroll at least 30 partici-
pants (15 participants in the intervention group and 15
participants in the control group). The recruitment
period is over 12 months (48 weeks). Recruiting at least
30 participants at each study site is considered feasible
given that at least 100 patients visit each pharmacy per
day. Assuming each study site will recruit 1 participant
every week, the 30 needed participants will be recruited
in 30 weeks (approximately 8 months). An extra 16
weeks of recruitment time is given to study pharmacists
to account for workload, holidays and sickness.
Discussion
This study is the first randomized controlled trial con-
ducted within Qatar and the Middle East (ME) to test
the effect of a pharmacist-delivered smoking cessation
program on smoking cessation rates. Furthermore, it is
the first study in Qatar to assess the change in health-
related quality of life after quitting smoking.
Having the economic analysis component in this study
is also of unique significance. To our knowledge, there are
no economic studies that have evaluated the economics of
a smoking cessation program in Qatar or the region. This
component is important as in settings where resources are
scarce, proving that an intervention brings a good return
to the investment can be as important as proving the
intervention effective.
Indeed, in consideration of limited resources and tight
departmental budgets, the additional spending associ-
ated with any of the study options should be examined.
This will be performed through determining the man-
agement option that yields benefits that are associated
with most health costs savings. For example, the struc-
tured program in this study is expected to have a favor-
able comparative effect profile. But if the value that is
associated with these advantages is not high enough,
having the structured program in settings may not be
the priority practice to implement. Here, the currentstudy provides a great opportunity for such analysis, see-
ing that randomized controlled trials are the ideal source
of data (i.e., highest level evidence) to be used in the
construction of economic analyses.
This study will be of significance to Qatar, the ME and
to some extent the world. It will advance knowledge
about the role that the ambulatory pharmacists in Qatar
and possibly in the ME can play in smoking cessation. It
will show to what extent these pharmacists would be
effective in helping smokers quit smoking. This would be
important for Qatar and the ME given the high number of
cigarette smokers in these countries [49]. This study will
also help in comparing the effect of pharmacist-delivered
smoking cessation programs in Qatar with the effect of
pharmacist-delivered smoking cessation programs in other
countries. Many previous studies conducted in Australia,
Europe and the USA have demonstrated the effectiveness
of pharmacist-run smoking cessation programs [12-20].
Extrapolating the results of these studies to Qatar and the
ME is not readily applicable. The pharmacy practice envir-
onment in these countries differs from that in Qatar. The
pace of improvement in ambulatory pharmacy practice in
Qatar, as other ME countries, is slow. Except for a few
cognitive and patient-oriented activities, ambulatory phar-
macists’ job is limited to prescription processing and
medication dispensing [50]. Nevertheless, Qatar’s phar-
macists are increasingly interested in defining a well-
recognized vocation for themselves in today’s healthcare
system and in moving their focus from pharmaceutical
products to patients. This study will be of potential sig-
nificance to ambulatory pharmacists in Qatar. It will
put them in a broader perspective than the product-
dispensing context. It will promote their role as public
health educators and accessible sources of health infor-
mation. Ambulatory pharmacists are an essential part
of the healthcare system in Qatar and are an existing
workforce that needs to be given the opportunity to
contribute to patient care. By direct involvement of these
pharmacists in smoking cessation, this study will help in
improving their professional role and in shifting it to a
more patient-centered focus and will assist them in having
better integration into the healthcare team in Qatar.Trial status
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